VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

B. melitensis lipopolysaccharide (LPS) vaccine
Vaccine Information
  • Vaccine Name: B. melitensis lipopolysaccharide (LPS) vaccine
  • Target Pathogen: Brucella spp.
  • Target Disease: Brucellosis
  • Vaccine Ontology ID: VO_0000311
  • Type: subunit vaccine
  • Antigen: B. melitensis strain 16M lipopolysaccharide (LPS)
  • Preparation: The LPS was extracted from killed cells and purified by a modification of the method of Bundle et al (Bhattacharjee et al., 2006).
  • Virulence: None.
  • Description: LPS, an outer membrane endotoxin common to gram negative bacteria, consists of three parts: Lipid A, a core oligosaccharide, and an O-antigen. The O-antigen is found in smooth strains only.
Host Response

Mouse Response

  • Vaccination Protocol: Groups of female BALB/c mice (Harlan Sprague-Dawley) were immunized by either i.n. or s.c. with purified B. melitensis LPS or LPS-GBOMP noncovalent complex vaccine. Control mice were immunized subcutaneously with sterile saline. Briefly, 25 µl of vaccine containing either 10 µg LPS or 10 µg LPS and 7.5 µg GBOMP contained in sterile saline was administered dropwise into the nostrils of anesthetized mice. Two doses of vaccine were given four weeks apart. For subcutaneous immunization, mice were given 10 µg vaccine in 200 µl sterile saline under the right hind thigh. A second dose of vaccine was given four weeks after the first dose. Blood was collected from five euthanized mice from each group four weeks after the first dose and four weeks after the second dose of vaccine. Sera were collected and stored at –20°C until analyzed for antibody. An enzyme-linked immunosorbent assay (ELISA) was used (Bhattacharjee et al., 2006).
  • Challenge Protocol: Groups of immunized mice (15 to 20 mice in each group) were challenged intranasally 4 weeks after the second dose of vaccine with 1x10^4 CFU of B. melitensis 16M suspended in 30 µl phosphate-buffered saline (PBS) (0.01 M sodium phosphate, 0.14 M sodium chloride; pH 7.5) as described previously (21). Blood, spleens, lungs, and livers were aseptically collected from anesthetized mice 8 weeks postchallenge. The numbers of Brucella CFU in organs were determined by dilution and culture on brucella agar as described previously (17). Serum was separated and stored at –20°C until it was used (Bhattacharjee et al., 2006).
  • Efficacy: Mice immunized subcutaneously with LPS vaccine showed significant protection against infection of the spleen (P < 0.001), liver (P < 0.001), and lungs (P < 0.05).
References
Bhattacharjee et al., 2006: Bhattacharjee AK, Izadjoo MJ, Zollinger WD, Nikolich MP, Hoover DL. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infection and immunity. 2006 Oct; 74(10); 5820-5. [PubMed: 16988260].